REGULAR CONTENT
Final ID
475
Type
Original Scientific Research-Oral or Pos
Authors
N Monfore1, K Conner2, J Wagner1, S Pant3
Institutions
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2N/A, Oklahoma City, OK, 3The University of Texas MD Anderson Cancer Center, Houston, TX
Purpose
To determine the rate of detecting metastatic disease or alternative diagnoses on imaged guided biopsy of lesions suspicious for metastatic disease in patients with known colorectal or pancreatic cancer.
Materials & Methods
IRB approval was obtained for this HIPAA compliant, retrospective study and the need for informed consent was waived. All imaged guided biopsies performed by radiology between 1/1/2009 and 7/1/2015 were retrospectively reviewed. Biopsies of lesions suspicious for metastatic disease in patients with an established pathologic diagnosis of colorectal or pancreatic cancer were included in the study. All relevant clinical, pathologic and imaging data were reviewed.
Results
Of the 129 biopsy procedures included in the study, 52 (40%) were performed on patients with colorectal cancer and 77 (60%) on patients with pancreatic cancer. 81% of biopsies (105/129, 74%-88%) confirmed metastatic disease compatible with the known primary malignancy. 4% of biopsies (5/129, 1%-9%) discovered a malignancy of a different type. 15% of biopsies (19/129, 9%-22%) were negative for malignancy, with 5% (7/129, 2%-11%) considered true negatives and 3% (4/129, 1%-8%) with insufficient follow-up information to determine true negative or false negative. 6% of biopsies (8/129, 3%-12%) were false negative. Combining the true negative and different type of malignancy results, 9% of biopsies (12/129, 5%-16%) yielded results that appropriately changed patient management. The presence of only 1 suspicious lesion or more than 1 suspicious lesion did not significantly change the likelihood of a malignant or benign result.
Conclusions
In patients with colorectal or pancreatic cancer and one or more lesions suspicious for metastatic disease, image guided biopsy potentially appropriately changed management in 9% of cases by revealing either nonmalignant disease or another type of malignancy. Inappropriate management would be possible in 6% of cases due to false negative biopsy results, indicating the need for follow-up of negative biopsy results.
Final ID
475
Type
Original Scientific Research-Oral or Pos
Authors
N Monfore1, K Conner2, J Wagner1, S Pant3
Institutions
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2N/A, Oklahoma City, OK, 3The University of Texas MD Anderson Cancer Center, Houston, TX
Purpose
To determine the rate of detecting metastatic disease or alternative diagnoses on imaged guided biopsy of lesions suspicious for metastatic disease in patients with known colorectal or pancreatic cancer.
Materials & Methods
IRB approval was obtained for this HIPAA compliant, retrospective study and the need for informed consent was waived. All imaged guided biopsies performed by radiology between 1/1/2009 and 7/1/2015 were retrospectively reviewed. Biopsies of lesions suspicious for metastatic disease in patients with an established pathologic diagnosis of colorectal or pancreatic cancer were included in the study. All relevant clinical, pathologic and imaging data were reviewed.
Results
Of the 129 biopsy procedures included in the study, 52 (40%) were performed on patients with colorectal cancer and 77 (60%) on patients with pancreatic cancer. 81% of biopsies (105/129, 74%-88%) confirmed metastatic disease compatible with the known primary malignancy. 4% of biopsies (5/129, 1%-9%) discovered a malignancy of a different type. 15% of biopsies (19/129, 9%-22%) were negative for malignancy, with 5% (7/129, 2%-11%) considered true negatives and 3% (4/129, 1%-8%) with insufficient follow-up information to determine true negative or false negative. 6% of biopsies (8/129, 3%-12%) were false negative. Combining the true negative and different type of malignancy results, 9% of biopsies (12/129, 5%-16%) yielded results that appropriately changed patient management. The presence of only 1 suspicious lesion or more than 1 suspicious lesion did not significantly change the likelihood of a malignant or benign result.
Conclusions
In patients with colorectal or pancreatic cancer and one or more lesions suspicious for metastatic disease, image guided biopsy potentially appropriately changed management in 9% of cases by revealing either nonmalignant disease or another type of malignancy. Inappropriate management would be possible in 6% of cases due to false negative biopsy results, indicating the need for follow-up of negative biopsy results.